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Background: Since 2009 some German health insurance companies have implemented integrated mental health
care services along the principles of assertive community treatment in collaboration with local mental health
service providers across Germany. Focus of this study is the analysis of effectiveness and cost-effectiveness of this
integrated care programme compared to care as usual in routine care surroundings in five regions in Germany.
Methods: In this 18-month multi-centre observational trial 250 patients enrolled in an integrated mental health care
programme and 250 patients who receive treatment as usual from five catchment areas will be included. In
addition, in each group about 125 relatives of the participating patients will be included. The primary outcome
criterion is the improvement of empowerment; secondary outcomes are subjective quality of life, functional
impairment and costs of illness. Data will be collected at baseline and three follow-ups after 6, 12 and 18 months.
Data will be analysed by means of mixed effects regression models. Propensity score methods are used for selection
bias control.
Discussion: Study results are expected to provide information about how integrated care programmes in their
present form contribute to the improvement of mental health care. In addition, the study will provide hints to
weaknesses of the current integrated care programme and options to overcome them. The major strengths of this
study are the real-world character of the study intervention with a simultaneous high level of academic rigour.
However, the fact that patients are not randomised to study groups and that there is no blinding might limit
the study.
Trial registration: German Clinical Trial Register DRKS00005111.
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Cost-effectivenessBackground
Contemporary treatment of people with permanent
severe mental illness is not only aimed at the control of
symptoms of disease but also aims at the empowerment
of patients by increasing their capacities for a largely
independent lifestyle and comprehensive social and
professional inclusion. For this purpose adequate mental
health care requires a broad spectrum of medical and* Correspondence: Annabel-Sandra.Stierlin@bkh-guenzburg.de
1Department of Psychiatry II, Ulm University, Bezirkskrankenhaus Günzburg,
Germany
Full list of author information is available at the end of the article
© 2014 Stierlin et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.psychosocial services. In order to keep the level of
psychiatric inpatient treatment and institutional care as
low as possible these services should be provided by
multi-professional community mental health teams
organized according to the principles of Assertive
Community Treatment (ACT).
The concept of ACT has already been developed and
tested in the 1970s in the USA. In line with the ACT
model, Stein and Santos [1] developed a concept for a
comprehensive multi-professional psychiatric treatment
programme in the immediate residential environment of
the patient which still serves as a model for communityLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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several modifications of the ACT concept, as intensive case
management (ICM), community mental health teams
(CMHT), and home treatment (HT) were developed to
account for specific requirements and conditions of
the respective structures of psychiatric care.
In a systematic review on the effectiveness and efficiency
of these treatment approaches for the period between
1979 and 2003, Roberts et al. evaluated a total of 48
publications written in English, of which 18 were
from the United States and 15 from the United Kingdom.
Twelve of the studies examine the cost-effectiveness of
ACT in comparison to the respective psychiatric standard
care during the period 1972 to 1996, the others focus
on case management, community psychiatric nurses
and other forms of community psychiatric care [2].
The authors conclude on the basis of the included
studies – as already done in a previous review [3] - that the
investigated ACT programmes, with few exceptions, prove
to be more efficient compared to inpatient treatment [2].
Rosen et al. [4] and Knapp et al. [5] came to a similar
conclusion. For case management and intensive case
management programmes, the authors concluded that
case management compared with standard inpatient
treatment is cheaper and more effective, but there are
no differences compared to standard outpatient treatment
[2]. Roberts et al. claim that data are inconclusive for
the other treatments which were investigated within
their review [2].
A Cochrane review by Marshall and Lockwood [6] of
ACT for people with severe mental disorders demonstrated
benefits of ACT compared to standard care with respect
to hospital admissions, length of hospital stay and, as
a consequence, reduced costs of hospital care. Even if
total costs are not lowered by ACT, patients benefit
from the intervention due to better accommodation
status, more employment and higher satisfaction scores.
Furthermore a lower loss-to-follow up-rate is reported.
Mental state and social functioning are not affected.
ACT is more effective even compared to case management
as regards duration of hospitalisation and costs of hospital
care [6].
These results are largely in agreement with the results
of another Cochrane review of intensive case management
[7]. This review planned to replace the previous one
written by Marshall and Lockwood. However, as the
new review focuses on intensive case management
(ICM), which, in this case, is defined as ACT and CM
in combination with a caseload less than 20 [7], the
older review remains crucial concerning ACT itself.
In general, the updated review reported fewer effects
than the former one. For example, there is no longer
a benefit as regards employment status, and data for cost
reduction are inconclusive. Burns et al. [8] assume that theinconsistent effects over recent years might be explained
by differences in trial contexts. In the meantime, welfare
systems have developed a number of interventions with a
view to reducing hospitalisation. Thus, control groups
might be contaminated with other care services and
consequently, effect sizes could be reduced. Burns et al.
showed, in a systemic review including 29 trials, that the
more ICM is adherent to the ACT model, the lower is
duration of hospitalisation. Moreover, benefits regarding
use of hospital care are more pronounced in patients with
a high baseline level of hospitalisation. As new welfare
systems generally aim at lower reliance on hospitals,
use of hospital care at baseline is reduced in newer studies
and consequently, significant reduction in costs for hospital
care and also in total costs is more difficult to obtain. Thus,
clinical benefits become more and more important to
justify the implementation of ACT services [3].
In summary, there is very good evidence for the effective-
ness of ACT compared to inpatient treatment and standard
care, because it achieves better results in terms of reducing
social impairments at comparable costs. However, effective-
ness and cost-effectiveness of each community mental
health care programme has to be evaluated in its special
setting both in terms of real implementation and in terms
of patients’ characteristics. Attention must be paid to un-
changed costs not outweighing clinical and social benefits
as in the end cost-effectiveness is what really counts.
The situation of mental health care services in Germany
Germany is one of the countries with highest expenditure
for mental health care in the world. However, in contrast to
other western European countries, psychiatric treatment in
Germany is still mainly provided by psychiatric hospitals,
outpatient clinics and office based psychiatrists and
only rarely by community mental health teams. As mental
health policy, except the provision of pharmaceutical treat-
ment, is the responsibility of the federal states, no national
mental health plan exists. Therefore, community mental
health care systems vary widely with regard to conceptual,
organisational and economic conditions across the country.
Moreover, the fact that different components of community
mental health care are funded by different payers (and on
different legal bases) hampers coordination and integration
of services.
Meanwhile an increasing number of experts suspect
that the lack of national standards for community
mental health care provision leads to deficits in service
effectiveness and efficiency. As the only possibility to
directly influence the design of community mental
health care, the federal government, in recent years,
has introduced several changes to the Social Security Code
which forms the legal basis for health care financing.
These legal changes allowed health insurance companies
to enter into contracts with medical or non-medical
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complex medical and psychosocial services for people
with mental disorders which is a basic requirement for the
provision of assertive community treatment. As a result of
these legislative changes, some of the 146 German health
insurance companies started to implement integrated
mental health care services along the principles of ACT in
collaboration with local mental health service providers.
To date, there are only few systematic trials on the
effectiveness and cost-effectiveness of these integrated
services. Only regional pilot projects have been evaluated
and most of these studies are limited by methodological
shortcomings.
Within the framework of an analysis of a programme
for integrated care (IC) of patients with schizophrenia
developed on the basis of the ACT approach Karow et al.
concluded that patients who were treated in the
ACT programme showed a greater improvement in
psychosocial and clinical outcome parameters after
12 months than patients in routine care. This study also
showed a reduction in expenses for inpatient treatment
with a simultaneous increase in expenses for outpatient
treatment and no significant differences in total costs
between both programmes were revealed. However, as part
of a cost-effectiveness analysis, the authors demonstrated
that treatment efficiency (relationship between treatment
costs and gain in quality of life) in the ACT group
was better than in routine care [9,10].
As result of a mirror design study Fischer et al.
concluded that IC reduces inpatient hospitalisation by
offering a complex range of services in the outpatient
setting. However, there is only a shift from inpatient
treatment to outpatient care and total expenditures
did not change significantly [11].
Hence, studies conducted in Germany confirm the
results of international studies: intensified outpatient
services do not contribute to a reduction of psychiatric
treatment costs but to increased efficiency of psychiatric
treatment. The results of the research Karow et al. [9]
suggest that, in these cases, similar effects were
achieved irrespective of programme design. However,
since only pilot projects have been investigated so far,
a verification of these effects and the identification of
influencing factors under real life conditions of care
are pending.
Also, research needs to address the issue of whether
integrated care programmes affect relatives or informal
carers living with patients with severe mental disorders.
It is assumed that family members and informal carers
perceive greater personal involvement in integrated care
programmes as positive. On the other hand, there is a
possibility that the shift of treatment from the inpatient
to the outpatient sector is associated with additional
burden for relatives and informal carers.While most of the earlier contracts on integrated
psychiatric care were limited to particular regions,
one of the larger health insurance companies started in
2009 to enter into identical contracts named “Network for
mental health” (NWpG) with different service providers
in different regions across the country. Meanwhile other
health insurance companies have also initiative NWpG
contract projects, and the number of enrolled patients has
increased to about 9000.
For this purpose, the focus of this study is the analysis
of effectiveness and cost-effectiveness of contracts for
integrated care programmes according to NWpG
compared to care as usual in real-world surroundings
(routine-care) in five regions in Germany. The main
outcome criteria are improvement of empowerment
as well as improvement of patients’ subjective quality
of life. Moreover, the effects of NWpG contracts for
integrated care programmes on burden and quality of
life of relatives will be evaluated. The results of this
study will contribute to a better understanding of the
need for outpatient and inpatient psychiatric care and




Although the randomised clinical trial is considered the
gold standard for examining the efficacy of mental
health care interventions, legal and organisational
aspects prevent this design being applied in the current
study: The implementation of integrated care programmes
took place on the legal basis of the German social code
which authorises the health insurances to define the
criteria for the eligibility of patients to enrol in integrated
care programmes. In addition, the social code gives
patients the right to be informed by sickness funds about
the opportunity to enrol in an integrated care programme.
If a patient fulfils the eligibility criteria, he or she will be
informed by the health insurance and asked for the
permission to transmit his or her contact data to the
local integrated care provider. After the patient gives
his or her permission to the sickness fund the local
service provider contacts the patient and invites him
or her to attend an informative meeting. On the basis
of this interview the service provider decides if the
patient will be offered enrolment or not. Finally, the
patient decides whether to enrol or not.
Therefore, we decided to design this study as a
prospective observational controlled trial comparing
patients with severe mental disorders enrolled in an
NWpG integrated care programme with patients
who received standard care in five federal states
(Schleswig-Holstein, Northrhine-Westfalia, Berlin, Saxony
and Bavaria) covering a broad range of catchment areas
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mental health service systems and with different providers
of ACT services. Trial duration is 18 months. Data will be
collected at baseline and there will be three follow-ups
after 6, 12 and 18 months.
Due to preference-based allocation blinding of patients
is not feasible. Furthermore, it is not possible to blind
the research associates because they would be unblinded
at the latest documenting integrated care service use in
the Client Socio-Demographic and Service Receipt
Inventory (CSSRI).
Intervention
Participants in the intervention group receive access
to integrated care services in addition to routine care. The
agreements under the NWpG model for IC comprise the
coordination and provision of outpatient psychiatric treat-
ment and care services through mobile multi-professional
teams under professional medical supervision.
Remuneration of IC contracts is based on staggered,
case-related lump sums: On the one hand, it allows for
extensive design flexibility in the programme by the
service provider, on the other hand, it also transfers the
risk of budget responsibility to the service provider. This
risk results primarily from the fact that all costs for
treatment in psychiatric inpatient and outpatient clinics
must be financed from the lump sum. This so-called
‘malus’ regime does not apply to services by panel
psychiatrists or psychotherapists [12].
All services will be documented in the Client Socio-
Demographic and Service Receipt Inventory (CSSRI),
and therefore, region-specific design options can be
incorporated in the final analysis.
Integrated care according to NWpG contracts under §
140a et seq of Volume V of the Social Insurance Code
shares the following basic components in each region:
 individual comprehensive case management on the
basis of main control centres;
 outreach mental health services including social
environment through home treatment;
 low-threshold and need adapted outreach
therapeutic care by multi-professional teams
under professional medical supervision, including
psychiatric nursing, socio-therapy, psychotherapy,
psycho-education and crisis intervention;
 guarantee for 24-hours crisis support 7 days a week;
 provision of retreat areas for crisis support outside
hospital settings;
 continuous cooperation with patients,
relatives and legal representatives to activate
existing resources and to strengthen self-help
potentials (empowerment) of those affected
[12,13].Care as usual
The range of offers for patients in the control group
(CAU) is restricted to standard care. They do not receive
access to the services assigned to integrated care.
Main aspects of usual care in Germany include mental
health care offered in institutions such as hospitals,
day-hospitals, medical practices, medical care units
and outpatient clinics of psychiatric institutes. Dependent
on disease severity, patients are entitled to receive special
therapies such as psychotherapy or occupational therapy.
Patients have access to socio-psychiatric services,
contact and counselling centres and self-help groups.
In some cases, patients experience additional support
from nurses, social workers or crisis support teams. In
sum, offers of mental health services are wide-ranging but
they vary from place to place.
Measurement instruments
The primary outcome will be measured by means of the
questionnaire for the assessment of empowerment in
patients with affective and schizophrenic disorders (EPAS).
The EPAS measures empowerment as the patient’s
perceived opportunity to control their own living
circumstances on five dimensions: “daily living”, “social
relationships and sexuality”, “psychiatric treatment”, “hope
and self efficacy” and “self esteem”. Additional subscales
are available for patients who are employed and for
parents of minor children. The EPAS core module
has 33 items and a Cronbachs Alpha of .94 was obtained
for the total scale [14].
The secondary outcome measures include 1) reduction in
psychosocial and clinical impairment using HoNos [Health
of the Nation outcome scale] [15-18], 2) improvement of
subjective quality of life using WHO-QoL-BREF [World
Health Organisation Quality of Life-short version] [19], 3)
reduction of unmet needs for psychiatric and psychosocial
services using CAN-EU [Camberwell Assessment of
Need-European Version] [20,21], 4) increase in satisfaction
with psychiatric treatment using ZuF8 [questionnaire to
treatment satisfaction] [22,23], 5) reduction of utilisation of
stationary and simultaneous increase in utilisation of
ambulatory medical and psychosocial services using
CSSRI [Client Socio-Demographic and Service Receipt
Inventory] [24], 6) reduction of direct and indirect
healthcare costs using CSSRI [24], 7) reduction of costs of
recovering a “healthy” year of life (QALY) using EQ-5D
[Euro Quality of Life – 5 dimensions] [25].
An additional study-specific questionnaire will be used at
visit 2, 3 and 4 to gain ancillary information as regards the
importance of and the satisfaction with local community
mental health services from the patients’ perspective.
There is the following set of outcome measures for
relatives and informal carers: 1) Change in perception
of burden related to support of patient suffering serious
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Questionnaires] [26], 2) change in subjective quality of life
using WHO-QoL-BREF [19] and 3) change in satisfaction
with psychiatric treatment using ZuF8 [22,23].
Sample Size calculation
The sample size calculation is performed for the change
in the empowerment total score over 18 months. An
effect size of f = 0.2 was assumed to be clinically relevant
for the within-between interaction of group*time in
repeated-measurements ANOVA with two groups and
four time-points of measurement.
Based on this effect size, a power of 0.90, and an alpha
level of 0.05, a total sample size of n = 350 is needed.
Sample size was further estimated based on a drop-out rate
of 30 %, according to experience from the ELAN-study
[27,28]. Based on this assumption, a total of 500 patients
will be recruited for visit 1. The sample size was calculated
using G-Power.
All participating patients will be asked to nominate a
relative/informal carer who has regular contact with
the patient and who supports the patient with regard
to disease-related burden. It is expected that relatives/
informal carers of about 50 % of patients will participate in
the study. Thus, the sample size for persons of reference
will be equal to n = 250. Using a repeated-measurements
design with four time-points of measurements this sample
size will concede the demonstration of an effect with
effect-size f = 0.2 and a significance level of alpha = 0.05
with a power greater than 0.75.
Trial inclusion and exclusion criteria
According to the eligibility criteria for the enrolment in the
NWpG care programmes patients will be included in the
study if they have been diagnosed as having a mental illness
of the categories F20-F29, F30-F39, F40-F48, F50, F60-F62,
F68-F69 and F91- F94 after ICD-10 during the last
12 months. Patients with a primary diagnosis of substance
use disorder (F10-F19, ICD-10) will be only included if they
have a psychotic disorder due to substance use.
In addition, patients should have either had a psychiatric
inpatient admission or an ambulatory prescription of
antipsychotic, anxiolytic or antidepressant drugs during
the last 12 months.
Patients must be in the age range of 18 to 80 years,
and patients with a care level are excluded.
Group allocation is performed on the basis of the type
of care provision intended for the coming 18 months.
Trial recruitment process
A total of 500 patients, in detail 50 IC patients and 50
CAU patients in each of the five regions and half as many
(250) relatives will be recruited via multiple settings. Re-
cruitment will be organised by local research associates.The patients for the intervention group will be informed
about the study mainly at introductory sessions for general
registration for integrated care by service providers.
Patient recruitment for the control group occurs with
the assistance of cooperating psychiatric/psychosocial
institutions (e.g. resident physicians and socio-psychiatric
services). Moreover, patients who decline integrated care
after the introductory session will be asked to participate
in the control group. Posters and flyers advertising the
study are also distributed at potential recruitment sites
(e.g. medical practices).
Cooperating psychiatric health institutions that agreed
to inform their patients about the study will exchange
personal contact details of patients interested in the study
with the associate on a regular basis. Written patient
information is about the aim of the study, benefits
and risks of participation and the study procedure.
Subsequently, the associate contacts the patient and checks
patient eligibility. If patients meet all of the inclusion and
none of the exclusion criteria, they are selected for the
study, and an appointment for visit 1 will be set. At visit 1,
patients are asked to nominate a relative/informal carer
who can be contacted by study staff regarding participation
in the study. Patients should provide detailed information
material about the study to the person nominated. If the
person is interested, he or she is asked to contact the local
research associate. If there is no reply, research associates
will call the patient once again.
Trial consent procedure
Patients interested in the study can choose either to
contact the research associates themselves or to sign a
written consent form that contact data can be submitted
from cooperating psychiatric health institutions to the
research associate and that the research associate is allowed
to call the patient.
At the beginning of visit 1, patients will be informed
once more with verbal and written information regarding
the study, and patients are asked to give written informed
consent if they agree to participate in this study. This will
be done by local research associates.
Patients are informed that they can withdraw at any
time without having to disclose reasons.
Registration in the integrated care programme occurs
completely independent of patients’ decision to participate
in the study or not.
Patients are asked to nominate an informal carer/relative
who can be interviewed with patient approval. Participation
of relatives/informal carers requires the written consent of
the patient and of the person of reference him- or herself.
Data collection/management process
In the context of this study patients will be interviewed
four times, every 6 months: baseline (visit 1), 6 months
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(visit 4). The first assessment (baseline, visit 1) in the
intervention group should be within the first month
patients are registered in the integrated care programme.
Follow-up windows are defined as plus/minus 4 weeks
for the intended time-point (6 months, 12 months or
18 months). There will be a subgroup-analysis eliminating
data collected outside these windows.
All clinical interviews will be conducted in rooms of
outpatient institutions or at patient’s homes by trained
research associates. Research associates are graduates
in psychology or nursing. Outcomes are measured by
self-report and face-to-face interviews.
There is the same time sequence of assessments for
relatives/informal carers as there is for patients. There are
also four assessments: at baseline, 6 months, 12 months
and 18 months after baseline. Between the patients’ and the
relatives’ visits, there should be less than four weeks.
Outcomes are rarely measured in face-to-face interviews.
Mostly, relatives/informal carers fill out the questionnaires
on their own and send them by mail - if necessary specific
issues are clarified by phone.
Quality assurance
All research associates were issued with several standard
operating procedures as to good clinical practice,
recruitment, realisation of study visits, completion
of questionnaires and of study documents, etc. A special
training (e.g. training in HoNos evaluation) of the research
associates is part of several project meetings. The
study coordinator oversees the whole study process
by communicating frequently with research associates
as regards outstanding issues, checking the data collection
procedure and sending queries if necessary. Some on-site
monitoring visits are planned. During the whole study
process research associates are tested for inter-rater
reliability for HoNos using case vignettes.
Planned analysis
A detailed statistical plan will be developed and put
down in writing prior to the analysis of data. Data
capturing is performed using IBM SPSS 21. Data analysis
will be carried out using IBM SPSS 21, STATA 12 and
SAS 9.3.
Baseline characteristics of the study population will
be summarised separately within each study group.
Categorical baseline variables will be compared between
intervention and control group using chi-square tests. The
continuous variables will be compared using t-test and
Mann–Whitney U test. Descriptive statistics of all out-
comes will be provided for all study groups at different
time points. Outcomes will be summarised in terms of the
total scores, and the proportion of patients improving
from baseline.The main analysis will be conducted on the intention-
to-treat (ITT) population.
Measures for bias control
Adjustment based on the propensity score method
will be used to control the selection bias [29]. The
estimation of propensity scores will be made on the basis
of logistic regression models including independent
variables such as medical history, patient’s clinical
condition, socio-demographic characteristics and current
living conditions [28].
Dealing with missing values
Missing values will be handled using the method of
multiple imputations [30]. Missing data will be imputed
10 times. Then, each of the completed datasets will be
analysed using the proposed statistical method. Final
results will be drawn from the average analysis of each of
the completed datasets using Rubin’s Rule.
Statistical analysis
The primary outcome is the change in empowerment
total score of EPAS over 18 months. Normal distribution is
assumed. This will be checked, and if found to be lacking
than appropriate solution strategies will be applied. Data
analysis for the primary outcome will be performed using
analysis of variance with repeated measurements with a
time effect, a group effect and an interaction effect between
time and study group.
In addition, secondary analysis for the primary outcome
will include a per-protocol (PP) approach. The PP
population will exclude all subjects in the ITT population
who meet any of the following criteria:
– change of study group during study process
– non-compliance or infrequent use of integrated care
by volunteers in the IC group
– more than four weeks between registration to
integrated care and visit 1 for patients in the
IC group
– visit 2, visit 3 and visit 4 were outside initially
planned time periods (more than +/− 1 month to
intended time points: 6 months, 12 months or
18 months after visit 1)
This additional analysis assesses the maximal intervention
efficacy in ideal conditions based on comparable outcome
measurements.
For secondary endpoints mixed-effect regression models
will be used. The random effect of time as well as the
interaction effect of time and study group will be adjusted
for propensity scores [28].
Within the frame of health economic evaluation based
on the net benefit approach, multivariate regression models
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calculated adjusted for the propensity scores. The
cost-utility relation is defined as the ratio of direct
and indirect costs and the change in QALYs [31-34].
Change in QALYs will be calculated on the basis of
EQ-5D questionnaire. All costs will be calculated from a
societal point of view, for that reason total costs of care
were considered and not just out-of-pocket payments.
Furthermore, production losses due to time off work for
those in employment will be included in the analyses.
Ethical considerations
The informed consent procedure is described in the
section “trial consent procedure”.
All patients enjoy freedom of choice as regards their
utilisation of health-related services. However, routine
care provision is expanded by integrated-care specific
services (e.g. hometreatment) for patients registered in
IC programmes. No patient group is disadvantaged
regarding clinical care. Decisions concerning medical
treatment and hospitalisation are performed by inde-
pendent physicians as required. There are no adverse
events expected to be related to the integrated care
specific services.
Allocation to study groups depends on decisions of
statutory health insurances and on patients’ preferences,
completely independent of the study. No costs are
imposed on patients, and all patients receive 10 € per
visit to cover minor expenses.
The obtained data are strictly confidential.
Source documents are specified only by code. Using
that code, data are entered into the electronic database.
Source documents are maintained in a locked up cabinet
in a room in the bureau of the local research associates
or of the research coordinator settled at the University
of Ulm. Source documents are scanned and sent by mail
to the research coordinator for central data-entry just
after the interview. Source documents are collected at
study sites over two to three months, and will then be
shipped to the research coordinator.
The research coordinator oversees the whole study
procedure, and she receives progress reports of the
project in each centre, if necessary, to make decisions
with regard to recruitment strategies or undesired events.
The study is being conducted in compliance with the
Declaration of Helsinki 2013.
It has been approved by the Ethics Committee of
the University of Ulm on 3rd May 2013 (application
number: 129/13 and by the Ethics Committee of the
TU Dresden on 30th September 2013 (application number:
EK 259072013).
This trial is registered with DRKS (German Clinical
Trials Register) and ICTRP (International Clinical Trials
Registry Platform) with the identifier DRKS00005111.Discussion
This multi-centre controlled study examines the effective-
ness and efficiency of contracts of integrated care in
patients suffering serious mental illnesses in routine
care surroundings. This is the first independent trial in
Germany examining the impact of integrated care pro-
grammes pursuant to NWpG contracts on empowerment,
quality of life, patient satisfaction and health economic
measures.
As a major strength of this study, the effectiveness and
the efficiency of integrated mental health care will be
observed under real world conditions. Research in real
life conditions might be more difficult but it will pay off
further effort when it comes to external validity of the
results. Since the intervention will be delivered by
the local integrated care providers in the regional
community mental health setting, it can be expected
that service provision varies in spite of the fact that
the same basic service components have to be provided in
each region. In addition, study regions vary with regard
to available standard care services and general living
circumstances. Furthermore, the study sample will reflect
the full heterogeneity of patients with severe mental
illness. This heterogeneity of the real world setting
provides the opportunity to examine the impact of a broad
range of individual and environmental characteristics on
the outcome of mental health care.
To make full use of this potential, high levels of academic
rigour will be maintained by the involvement of independ-
ent, trained research associates and the application of stan-
dardised measurement tools, a strict monitoring and quality
control for data collection and management and the appli-
cation of advanced statistical methods for data analysis.
The preference-based allocation of study participants
might be the major target of criticism as it is suspected
to introduce a selection bias. Preference-based allocation
was mainly chosen due to the legal and organisational
framework of NWpG contracts in Germany. But it also
holds the benefit of reality proximity of the intervention
and thus contributes to external validity of study results.
Selection bias will be controlled by means of propensity
score adjustment. However, it cannot be guaranteed
that all factors possibly causing a selection bias can be
measured and included in the analysis.
Standard care is permanently undergoing a change. An
example is the inclusion of ever more interventions with a
view to reducing hospitalisation. Thus, historical data will
not be up to date, and it is imperative to simultaneously
examine changes in patients receiving standard care.
There will be regional differences in the development of
mental health care services, too. However, based on the
Client Socio-Demographic and Service Receipt Inventory
we will be able to integrate such special regional care
features in IC as well as in CAU in the statistical analysis.
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The integrated mental health services examined in this
study are currently being tested in various parts of
Germany. However, systematic data on effectiveness and
efficiency are not available yet. The results of the
study will provide information for service providers
and purchaser organisations (health care funders) about
how integrated care programmes in their present form
contribute to the improvement of mental health care.
The focus will be on the ability of IC services to
overcome existing deficiencies at the interface between
outpatient and inpatient mental health care and their
performance from the point of view of patients, health
care funders and the national economy. In addition, the
study will provide hints to weaknesses of the current
NWpG model and options to overcome them.
Trial status
Currently recruiting status:
Ncurrent[patients, IC] = 228
Ncurrent[patients, CAU] = 170
Ncurrent[persons of reference, IC] = 105
Ncurrent[persons of reference, CAU] = 58
as of 7th may 2014
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